Skip to main content
Top
Published in: Molecular Cancer 1/2007

Open Access 01-12-2007 | Research

Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance

Authors: Pei-Yin Lin, Susan P Fosmire, See-Hyoung Park, Jin-Young Park, Shairaz Baksh, Jaime F Modiano, Robert H Weiss

Published in: Molecular Cancer | Issue 1/2007

Login to get access

Abstract

Background

The PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) tumor suppressor gene is frequently mutated or deleted in a wide variety of solid tumors, and these cancers are generally more aggressive and difficult to treat than those possessing wild type PTEN. While PTEN lies upstream of the phosphoinositide-3 kinase signaling pathway, the mechanisms that mediate its effects on tumor survival remain incompletely understood. Renal cell carcinoma (RCC) is associated with frequent treatment failures (~90% in metastatic cases), and these tumors frequently contain PTEN abnormalities.

Results

Using the ACHN cell line containing wild type PTEN, we generated a stable PTEN knockdown RCC cell line using RNA interference. We then used this PTEN knockdown cell line to show that PTEN attenuation increases resistance to cisplatin-induced apoptosis, a finding associated with increased levels of the cyclin kinase inhibitor p21. Elevated levels of p21 result from stabilization of the protein, and they are dependent on the activities of phosphoinositide-3 kinase and Akt. More specifically, the accumulation of p21 occurs preferentially in the cytosolic compartment, which likely contributes to both cell cycle progression and resistance to apoptosis.

Conclusion

Since p21 regulates a decision point between repair and apoptosis after DNA damage, our data suggest that p21 plays a key role in mechanisms used by PTEN-deficient tumors to escape chemotherapy. This in turn raises the possibility to use p21 attenuators as chemotherapy sensitizers, an area under active continuing investigation in our laboratories.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943CrossRefPubMed Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943CrossRefPubMed
2.
go back to reference Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60: 3605-3611.PubMed Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60: 3605-3611.PubMed
3.
go back to reference Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999, 96: 1563-1568. 10.1073/pnas.96.4.1563PubMedCentralCrossRefPubMed Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999, 96: 1563-1568. 10.1073/pnas.96.4.1563PubMedCentralCrossRefPubMed
4.
go back to reference Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003, 4: 209-221. 10.1016/S1535-6108(03)00215-0CrossRefPubMed Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003, 4: 209-221. 10.1016/S1535-6108(03)00215-0CrossRefPubMed
5.
go back to reference Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006, 441: 475-482. 10.1038/nature04703CrossRefPubMed Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006, 441: 475-482. 10.1038/nature04703CrossRefPubMed
6.
go back to reference Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, : Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998, 7: 507-515. 10.1093/hmg/7.3.507CrossRefPubMed Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, : Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998, 7: 507-515. 10.1093/hmg/7.3.507CrossRefPubMed
7.
go back to reference Lee JS, Kim HS, Kim YB, Lee MC, Park CS: Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003, 84: 166-172. 10.1002/jso.10289CrossRef Lee JS, Kim HS, Kim YB, Lee MC, Park CS: Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003, 84: 166-172. 10.1002/jso.10289CrossRef
8.
go back to reference Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M: Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol. 2005, 16: 928-933. 10.1093/annonc/mdi182CrossRefPubMed Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M: Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol. 2005, 16: 928-933. 10.1093/annonc/mdi182CrossRefPubMed
9.
go back to reference Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002, 99: 53-57. 10.1002/ijc.10303CrossRefPubMed Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002, 99: 53-57. 10.1002/ijc.10303CrossRefPubMed
10.
go back to reference Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U: Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 1999, 19: 3841-3846.PubMed Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U: Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 1999, 19: 3841-3846.PubMed
11.
go back to reference Sukosd F, Digon B, Fischer J, Pietsch T, Kovacs G: Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet Cytogenet. 2001, 128: 161-163. 10.1016/S0165-4608(01)00413-7CrossRefPubMed Sukosd F, Digon B, Fischer J, Pietsch T, Kovacs G: Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet Cytogenet. 2001, 128: 161-163. 10.1016/S0165-4608(01)00413-7CrossRefPubMed
12.
go back to reference Figlin RA, Seligson D, Wu H, Thomas G, Leppert JT, O'Toole T, Dukart G, Gibbons J, Belldegrun A, Pantuck AJ: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol. 2005, 23: 4539- Figlin RA, Seligson D, Wu H, Thomas G, Leppert JT, O'Toole T, Dukart G, Gibbons J, Belldegrun A, Pantuck AJ: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol. 2005, 23: 4539-
13.
14.
go back to reference Zhou M, Gu L, Findley HW, Jiang R, Woods WG: PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003, 63: 6357-6362.PubMed Zhou M, Gu L, Findley HW, Jiang R, Woods WG: PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003, 63: 6357-6362.PubMed
15.
go back to reference Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW: Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006, 66: 7639-7646. 10.1158/0008-5472.CAN-06-0419PubMedCentralCrossRefPubMed Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW: Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006, 66: 7639-7646. 10.1158/0008-5472.CAN-06-0419PubMedCentralCrossRefPubMed
16.
go back to reference Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Dev. 1999, 13: 1501-1512.CrossRefPubMed Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Dev. 1999, 13: 1501-1512.CrossRefPubMed
17.
go back to reference Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366: 701-704. 10.1038/366701a0CrossRefPubMed Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366: 701-704. 10.1038/366701a0CrossRefPubMed
18.
go back to reference Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75: 805-816. 10.1016/0092-8674(93)90499-GCrossRefPubMed Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75: 805-816. 10.1016/0092-8674(93)90499-GCrossRefPubMed
19.
go back to reference LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11: 847-862.CrossRefPubMed LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11: 847-862.CrossRefPubMed
20.
go back to reference Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A. 1998, 95. 10.1-1096.PubMedCentralCrossRefPubMed Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A. 1998, 95. 10.1-1096.PubMedCentralCrossRefPubMed
21.
go back to reference Weiss RH, Joo A, Randour C: p21Waf1/Cip1 is an assembly factor required for PDGF-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000, 275: 10285-10290. 10.1074/jbc.275.14.10285CrossRefPubMed Weiss RH, Joo A, Randour C: p21Waf1/Cip1 is an assembly factor required for PDGF-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000, 275: 10285-10290. 10.1074/jbc.275.14.10285CrossRefPubMed
22.
go back to reference Weiss RH, Marshall D, Howard L, Corbacho AM, Cheung AT, Sawai ET: Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). Cancer Lett. 2003, 189: 39-48. 10.1016/S0304-3835(02)00495-0CrossRefPubMed Weiss RH, Marshall D, Howard L, Corbacho AM, Cheung AT, Sawai ET: Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). Cancer Lett. 2003, 189: 39-48. 10.1016/S0304-3835(02)00495-0CrossRefPubMed
23.
go back to reference Fan Y, Borowsky AD, Weiss RH: An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther. 2003, 2: 773-782.PubMed Fan Y, Borowsky AD, Weiss RH: An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther. 2003, 2: 773-782.PubMed
24.
go back to reference Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2003, 4: 425-429. 10.1016/S1535-6108(03)00308-8CrossRefPubMed Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2003, 4: 425-429. 10.1016/S1535-6108(03)00308-8CrossRefPubMed
25.
go back to reference Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005, 436: 725-730. 10.1038/nature03918PubMedCentralCrossRefPubMed Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005, 436: 725-730. 10.1038/nature03918PubMedCentralCrossRefPubMed
26.
go back to reference Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD: p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007, 177: 63-68. 10.1016/j.juro.2006.08.073CrossRefPubMed Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD: p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007, 177: 63-68. 10.1016/j.juro.2006.08.073CrossRefPubMed
27.
go back to reference Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, Weiss RH: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006, 5: 64- 10.1186/1476-4598-5-64PubMedCentralCrossRefPubMed Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, Weiss RH: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006, 5: 64- 10.1186/1476-4598-5-64PubMedCentralCrossRefPubMed
28.
go back to reference Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994, 9: 2261-2268.PubMed Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994, 9: 2261-2268.PubMed
29.
go back to reference Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of p21Cip1/WAF1 enhances protein stability of p21Cip1/WAF1 and promotes cell survival. J Biol Chem. 2002, 277: 11352-11361. 10.1074/jbc.M109062200CrossRefPubMed Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of p21Cip1/WAF1 enhances protein stability of p21Cip1/WAF1 and promotes cell survival. J Biol Chem. 2002, 277: 11352-11361. 10.1074/jbc.M109062200CrossRefPubMed
30.
go back to reference Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001, 3: 245-252. 10.1038/35060032CrossRefPubMed Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001, 3: 245-252. 10.1038/35060032CrossRefPubMed
31.
go back to reference Ritt MG, Mayor J, Wojcieszyn J, Smith R, Barton CL, Modiano JF: Sustained nuclear localization of p21/WAF-1 upon growth arrest induced by contact inhibition. Cancer Lett. 2000, 158: 73-84. 10.1016/S0304-3835(00)00507-3CrossRefPubMed Ritt MG, Mayor J, Wojcieszyn J, Smith R, Barton CL, Modiano JF: Sustained nuclear localization of p21/WAF-1 upon growth arrest induced by contact inhibition. Cancer Lett. 2000, 158: 73-84. 10.1016/S0304-3835(00)00507-3CrossRefPubMed
32.
go back to reference Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH: Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2003, 16: 263-269. 10.1016/S0898-6568(03)00136-0.CrossRef Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH: Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2003, 16: 263-269. 10.1016/S0898-6568(03)00136-0.CrossRef
33.
go back to reference Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223PubMedCentralCrossRefPubMed Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223PubMedCentralCrossRefPubMed
34.
go back to reference Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage-induced apoptosis through inhibition of p21 translation. Cell. 2005, 120: 747-759. 10.1016/j.cell.2004.12.040CrossRefPubMed Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage-induced apoptosis through inhibition of p21 translation. Cell. 2005, 120: 747-759. 10.1016/j.cell.2004.12.040CrossRefPubMed
35.
go back to reference Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004, 22: 909-918. 10.1200/JCO.2004.08.185CrossRefPubMed Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004, 22: 909-918. 10.1200/JCO.2004.08.185CrossRefPubMed
36.
go back to reference Weiss RH, Lin PY: Kidney Cancer: Identification of Novel Targets for Therapy. Kidney Int. 2006, 69: 224-232. 10.1038/sj.ki.5000065CrossRefPubMed Weiss RH, Lin PY: Kidney Cancer: Identification of Novel Targets for Therapy. Kidney Int. 2006, 69: 224-232. 10.1038/sj.ki.5000065CrossRefPubMed
37.
go back to reference Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004, 101: 1545-1551. 10.1002/cncr.20541CrossRefPubMed Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004, 101: 1545-1551. 10.1002/cncr.20541CrossRefPubMed
38.
go back to reference Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF: Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002, 39: 458-472. 10.1354/vp.39-4-458CrossRefPubMed Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF: Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002, 39: 458-472. 10.1354/vp.39-4-458CrossRefPubMed
39.
go back to reference Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S: Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation in endothelial cells. Mol Cell Biol. 2001, 21: 5644-5657. 10.1128/MCB.21.16.5644-5657.2001PubMedCentralCrossRefPubMed Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S: Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation in endothelial cells. Mol Cell Biol. 2001, 21: 5644-5657. 10.1128/MCB.21.16.5644-5657.2001PubMedCentralCrossRefPubMed
40.
go back to reference Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M: Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell. 2003, 115: 71-82. 10.1016/S0092-8674(03)00755-4CrossRefPubMed Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M: Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell. 2003, 115: 71-82. 10.1016/S0092-8674(03)00755-4CrossRefPubMed
41.
go back to reference Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R: Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene. 1999, 18: 4313-4325. 10.1038/sj.onc.1202686CrossRefPubMed Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R: Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene. 1999, 18: 4313-4325. 10.1038/sj.onc.1202686CrossRefPubMed
42.
go back to reference Blagosklonny MV, Wu GS, Omura S, el Deiry WS: Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun. 1996, 227: 564-569. 10.1006/bbrc.1996.1546CrossRefPubMed Blagosklonny MV, Wu GS, Omura S, el Deiry WS: Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun. 1996, 227: 564-569. 10.1006/bbrc.1996.1546CrossRefPubMed
43.
go back to reference Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science. 2004, 303: 1179-1181. 10.1126/science.1092089CrossRefPubMed Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science. 2004, 303: 1179-1181. 10.1126/science.1092089CrossRefPubMed
44.
go back to reference Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA: Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther. 2006, 5: 713-722. 10.1158/1535-7163.MCT-05-0484CrossRefPubMed Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA: Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther. 2006, 5: 713-722. 10.1158/1535-7163.MCT-05-0484CrossRefPubMed
45.
go back to reference Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cytoplasmic p21Waf1/Cip1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003, 5: 242-249. 10.1186/bcr654.CrossRef Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cytoplasmic p21Waf1/Cip1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003, 5: 242-249. 10.1186/bcr654.CrossRef
46.
go back to reference Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL, Norbury CJ: Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur J Cancer. 2001, 37: 2405-2412. 10.1016/S0959-8049(01)00327-6CrossRefPubMed Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL, Norbury CJ: Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur J Cancer. 2001, 37: 2405-2412. 10.1016/S0959-8049(01)00327-6CrossRefPubMed
47.
go back to reference Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51: 6304-6311.PubMed Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51: 6304-6311.PubMed
48.
go back to reference Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992, 89: 7491-7495. 10.1073/pnas.89.16.7491PubMedCentralCrossRefPubMed Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992, 89: 7491-7495. 10.1073/pnas.89.16.7491PubMedCentralCrossRefPubMed
49.
go back to reference Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene. 2003, 22: 3113-3122. 10.1038/sj.onc.1206451CrossRefPubMed Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene. 2003, 22: 3113-3122. 10.1038/sj.onc.1206451CrossRefPubMed
50.
go back to reference Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J: Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 2006, 66: 1929-1939. 10.1158/0008-5472.CAN-05-1986CrossRefPubMed Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J: Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 2006, 66: 1929-1939. 10.1158/0008-5472.CAN-05-1986CrossRefPubMed
51.
go back to reference Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003, 3: 117-130. 10.1016/S1535-6108(03)00021-7CrossRefPubMed Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003, 3: 117-130. 10.1016/S1535-6108(03)00021-7CrossRefPubMed
52.
go back to reference Weiss RH, Randour CJ: Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1). Atherosclerosis. 2002, 161: 105-112. 10.1016/S0021-9150(01)00628-1CrossRefPubMed Weiss RH, Randour CJ: Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1). Atherosclerosis. 2002, 161: 105-112. 10.1016/S0021-9150(01)00628-1CrossRefPubMed
53.
go back to reference Fan YP, Weiss RH: Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol. 2004, 15: 575-584. 10.1097/01.ASN.0000114557.75244.5FCrossRefPubMed Fan YP, Weiss RH: Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol. 2004, 15: 575-584. 10.1097/01.ASN.0000114557.75244.5FCrossRefPubMed
54.
go back to reference Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE: Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. 1995, 47: 1462-1469.CrossRefPubMed Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE: Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. 1995, 47: 1462-1469.CrossRefPubMed
55.
go back to reference Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, Latif F, Downward J, Neel BG: The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell. 2005, 18: 637-650. 10.1016/j.molcel.2005.05.010CrossRefPubMed Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, Latif F, Downward J, Neel BG: The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell. 2005, 18: 637-650. 10.1016/j.molcel.2005.05.010CrossRefPubMed
Metadata
Title
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance
Authors
Pei-Yin Lin
Susan P Fosmire
See-Hyoung Park
Jin-Young Park
Shairaz Baksh
Jaime F Modiano
Robert H Weiss
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-6-16

Other articles of this Issue 1/2007

Molecular Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine